CTSB and breast cancer: It may downregulate phosphorylated insulin response substrate-1 (pIRS-1), pAkt, pMEK1/2, pERK1/2, cyclin D1, cyclin E, cathepsin D, cathepsin B, N-cadherin, Snail, Slug, RhoA, Rac1, MMP-9, MMP-2, monocarboxylate transporter 1 (MCT1), glucose transporter 1 (GLUT1) and may upregulate p-53, p21, and E-cadherin, resulting in decreased proliferation, metastasis, migration, and invasion of BC cells [84,85,86].